ReLink IV
Reducing intravenous (IV) catheter dislodgement
ReLink IV
IV dislodgement leads to catheter failures, with over 10% failing to meet their intended dwell time due to this issue.(1)
These occurrences can result in patient injuries, loss of fluid resources, and exposure to blood and hazardous medicine.(2, 3, 4) Dislodgement also creates additional work for healthcare professionals, requiring up to 30 minutes to reinstate the infusion.(5)
ReLink IV is a breakaway connector with double-sided, self-sealable valves, designed to disconnect under excessive force, thus protecting the IV catheter placement site.
​
After separation, both parts can be disinfected and reconnected, allowing for rapid reinstatement of IV therapy.
​
ReLink IV reduces accidental IV catheter dislodgement and minimises spillage of medicine and IV fluids.
Note: Pending CE certification
Benefits
-
Reduces IV catheter dislodgement frequency
-
Allows rapid reinstatement of IV therapy
-
Minimises spillage of medicine and fluids
Download
ReLink IV
Pump and gravity enabled IV therapy infusions
Available soon
References
-
Helm, Robert E et al. “Accepted but unacceptable: peripheral IV catheter failure.” Journal of infusion nursing: the official publication of the Infusion Nurses Society vol. 38,3 (2015): 189-203.
-
Nursing Advanced Skills [Internet]. Open Resources for Nursing (Open RN); Ernstmeyer K, Christman E, editors. Eau Claire (WI): Chippewa Valley Technical College; 2023.
-
Jagger, Janine et al. "Blood exposure risk during peripheral I.V. catheter insertion and removal." Nursing Critical Care vol. 7,6 (2012): 10-15.
-
Hodson, L et al. "Managing hazardous drug exposures: information for healthcare settings." U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, DHHS (NIOSH) Publication No. 2023-130.
-
Moureau, Nancy. "Impact and Safety Associated with Accidental Dislodgement of Vascular Access Devices: A Survey of Professions, Settings, and Devices." Journal of the Association for Vascular Access vol. 23,4 (2018): 203-215.
-
Results from a post-market randomised controlled trial of ReLink Care, MDD class Is device, at Uppsala University Hospital, Sweden.